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Abstract
Zoledronic acid (ZA) is an antiresorptive drug
used in children with bone diseases like osteo-
genesis imperfecta, juvenil osteoporosis, fibrous
dysplasia and primary bone tumors. The aim of
the present study was to evaluate the effects of
ZA dose accumulation on growing bone during
different periods of treatment in normal rats.
Methods: A 4x2 factorial design was used
to study the effect of the dose of ZA
(D: 0-2.5-12.5-25 µg Z/kg body weight/s.c.
weekly) and the length of treatment (T: 15-30
days) in normal female Sprague Dawley rats.
Bone morphometric, histomorphometric,
densitometric and biomechanical studies were
performed.
Results: Femoral length and cross-sectional
area were affected by both D and T. A signifi-
cant interaction between D and T was observed
in length with a lower value at higher dose and
30 days of treatment. Growth plate of the tibia
showed a decrease in total thickness with D
and T. Histomorphometric and connectivity pa-
rameters of trabecular bone were significantly
increased with D and several parameters were
also affected by T. Cortical bone strength was
increased only with T. Biomechanical parame-
ters of trabecular bone showed significant inter-
action with greater effect at higher D and T.
Conclusion: Even though a mild negative
effect of the highest dose of ZA on linear and
appositional growth was observed, the other
bone parameters evaluated were improved. A
careful risk/benefit analysis would lead us to
conclude that the mild deleterious effects of ZA
during growth are outweighed by the benefit
obtained with treatment.
Key words: bone growth, bone diseases, bone
strength, cartilage growth, zoledronic acid.
Resumen
EFECTO DEL ACIDO ZOLEDRÓNICO EN EL
HUESO DE RATAS EN CRECIMIENTO
El ácido zoledrónico (AZ) es un fármaco
antirresortivo utilizado en niños con enferme-
dades óseas como osteogénesis imperfecta,
osteoporosis juvenil, displasia fibrosa y tumores
óseos primarios. El objetivo del presente estu-
dio fue evaluar los efectos de las dosis acumu-
ladas de AZ en el hueso en crecimiento de
ratas hembras normales durante diferentes
períodos de tratamiento.
Métodos: se utilizó un diseño factorial de 4x2
para estudiar el efecto de la dosis de AZ
(D: 0-2,5-12,5-25 μg Z / kg de peso corporal /sc
semanalmente) y el período de tratamiento
(T: 15-30 días) en ratas Sprague Dawley. Se
realizaron estudios óseos morfométricos, histo-
morfométricos, densitométricos y biomecánicos.
Resultados: la longitud y el área de sección
transversal del fémur se vieron afectadas tanto
por D como por T. Se observó una interacción
significativa entre D y T en la longitud obtenién-
dose un valor más bajo a la dosis más alta y a
30 días de tratamiento. El cartílago de creci-
miento de la tibia mostró una disminución en el
espesor total con D y T. Los parámetros histo-
morfométricos y de conectividad del hueso
trabecular aumentaron significativamente con
D y varios parámetros también se vieron afec-
tados por T. La fortaleza ósea cortical aumentó
solo con T. Los parámetros biomecánicos del
hueso trabecular mostraron una interacción
significativa con un mayor efecto a mayor D y T.
Conclusión: a pesar que se observó un leve
efecto negativo de la dosis más alta de AZ
sobre el crecimiento lineal y aposicional,
el resto de los parámetros óseos evaluados
mejoraron. Un análisis cuidadoso del riesgo /
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beneficio permite concluir que los efectos
negativos leves del AZ durante el crecimiento
son superados por el beneficio obtenido con el
tratamiento.
Palabras clave: crecimiento óseo, enfermeda-
des óseas, fortaleza ósea, cartílago de creci-
miento, ácido zoledrónico.
Introduction
Bisphosphonates (BP) are antiresorptive
drugs widely used in clinical practice for the
treatment of bone diseases associated with high
bone turnover in adults1,2. BP are structural
analogs of pyrophosphate that bind to bone
mineral and inhibit bone resorption by acting on
osteoclasts3 and also show positive effects on
the viability of osteoblasts and osteocytes4. They
are increasingly used in pediatric patients with
osteogenesis imperfecta, juvenile osteoporosis,
fibrous dysplasia and primary bone tumors5-7.
Although they have been an effective option for
childhood bone diseases, as they showed
decrease in pain and fractures, their use in
children and adolescents continues to be
controversial. The most used BP in children is
pamidronate but zoledronic acid (ZA) is being
increasingly used because of its higher antire-
sorptive potency and reduced frequency of
administration8. Moreover, ZA has several antitu-
mor effects on various tissues and prevents
skeletal complications in different tumors9. It is
used with the usual chemotherapy in the treat-
ment of primary tumors, like osteosarcoma and
Ewing´s sarcoma, in children and adolescents10.
However, the information about safety and effi-
cacy of ZA in young patients is limited and there
are few published data about long-term use11-13.
Experimental studies have suggested that
BP administration may result in changes in the
growing skeleton. A study carried out on healthy
rats showed that alendronate causes a signifi-
cant decrease in femoral and tibial length, tibial
growth plate thickness, and longitudinal growth
of hemi-mandibles14. Also, alendronate pre-
vents the removal of calcified cartilage and ma-
turation of trabeculae15. Experiments in rabbits
treated with ZA showed bone resorption altera-
tions associated with cartilage matrix retention
and a decrease in tibial length16. Moreover, ZA
has been found to induce marked osteosclero-
sis in primary and secondary spongiosa in a
murine model of metastatic tumor, which gene-
rates a bone growth arrest during treatment17.
Pre-clinical observations are consistent with the
case of a patient who showed growth arrest for
10 months during treatment with ZA with normal
gain in size once the treatment had ended18.
Munns et al showed that bone formation rate
per bone surface of children with osteogenesis
imperfecta treated with pamidronate, was only
17% that of untreated osteogenesis imperfecta
patients and 25% of healthy controls19. Furhter,
endochondral growth was transiently disturbed
by high doses of ZA under primary bone tumors
treatment in pediatric patients18. However, it
was found that ZA decreased the number of
bone fractures and pain in children with osteo-
genesis imperfecta and osteoporosis, and
improved their functional status20.21. In addition,
ZA showed higher Z-scores for areal bone
mineral density (BMD) in lumbar spine and
vertebral reshaping in children with severe
osteogenesis imperfecta, but long-bones
fracture rates were still high22. Moreover, a
recent study showed an increase in lumbar
spine areal BMD and a higher final height
z-score in patients with osteogenesis imperfect
after BP treatment during growth13.
In summary, the data reported suggested
that BP may have a negative impact on bone
growth. As bone fragility in pediatric patients is
different from adults, making difficult the data
extrapolation, the clinical use of BP should be
carefully evaluated. Studies with antiresorptive
agents as BP in children are insufficient to
address all the concerns about its efficacy and
safety. There is not even a consensus on which
BP, dose, and treatment duration to use,
although experts recommend their limited use
for bone diseases8,9. Thus, the aim of the
present study was to evaluate the effects of ZA
dose accumulation on growing bone during
different periods of treatment in normal rats.
Materials and methods
Animals
Twenty-one day old female Sprague Dawley
rats (n=24) provided by the School of Medicine,
Rosario National University (Argentina) were
used. Rats were housed in a room with 12-h
light and dark cycles, and constant temperature
of 24±1ºC. All the experiments were conducted
in accordance with international guidelines for
animal care23 and have been approved by the
Bioethics Committee of our Institution.
A 4x2 factorial arrangement consisting of two
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factors (ZA dose [D] and length of treatment [T])
and its respective levels [D:0, 2.5, 12.5 y
25 µg/kg body weight, subcutaneously once
a week and T: 15 y 30 days] was performed.
Animals were randomly assigned into 8 groups
(each containing 3 animals). The period of
treatment factor had implicit the cumulative
dose of ZA and the animal growth. At the end of
each period of treatment, rats were euthanized
in a CO2 chamber and tibias and femurs were
obtained.
Bone mineral density
At the end of experiment, total BMD (mg
Ca/cm2) was determined on left tibias using
X-ray absorptiometry (Work Ray 70 KV, Work-
man SRL, Argentina) simultaneously with an
aluminum step wedge, which was previously
calibrated with known calcium concentrations24.
The total BMD was calculated using Image J
1.48 software (NIH, Maryland, USA).
Bone histomorphometry
The proximal epiphysis of the right tibias
were fixed in 10% phosphate buffered formal-
dehyde and decalcified in 10% EDTA before
embedded in paraffin. Five-μm longitudinal sec-
tions were stained with hematoxylin and eosin
and 3 sections per rat were examined. Digitali-
zed images were obtained with a light micros-
cope (Mikoba 320, China) and a digital camera
(Olympus SP-350, China). Analyses were per-
formed in a 2 mm2 area at 1 mm from growth
plate-metaphyseal junction. The following mea-
surements were performed25: 1) total tissue vo-
lume, TV (μm2); 2) trabecular bone volume, BV
(μm2); and 3) trabecular bone surface, BS (μm).
With these values, histomorphometrical varia-
bles were calculated: 1) bone volume, BV/TV
(%) = [BV*100/TV]; 2) trabecular thickness,
Tb.Th (μm) = [2/(BS/BV)]; 3) trabecular
number, Tb.N (1/mm) = [(BV/TV)/(Tb.Th)];
and 4) trabecular separation, Tb.Sp (μm) =
[(1/Tb.N)-Tb.Th]. On the same sections, growth
plate thickness (GPC.Th, µm), hypertrophic
cartilage thickness (HpZ.Th) and resting and
proliferative cartilage thickness (R&PZ.Th) were
measured on digital images. Measurements
were performed at three location (25, 50 and
75 % of cartilage width) within the growth plate
(3 measurements per location, see figure 1)26. All
the measurements were carried out by the same
operator in a blind fashion using the software
Image J 1.48 and they were averaged to obtain
a single value per tibia.
The analysis of trabecular interconnectivity
was performed as previously published24,27,
and the following parameters were measured
using ImageJ 1.48 software: total number of
nodes (Nd), number of node-to-node branches
(NNd), number of node-to-termini branches
(NNdTm), number of trees (T.N), number of
terminals (Tm), and number of branches with
two terminals (NTm). With these parameters,
we calculate the interconnectivity parameters:
interconnectivity index [ICI = Nd*NNd) / T.N*
(NNdTm+1)]; node-to-termini ratio [R= Nd/Tm]
and mean size of branches [Dist (mm) = ∑
branches size / (NNdTm+NNd+NTm)].
Bone measurements
Longitudinal growth was assessed by measu-
ring the femoral and tibia length using a digital
caliper (accurate ±0.01 mm). In order to assess
bone appositional growth, cross sections -500
μm in thickness- of right femoral diaphyses
were cut with a low speed saw (IsoMet. Buehler
Ltd. Illinois, USA). A digital image was obtained
at 40x magnification and the following measure-
ments were performed using Image J 1.48
software: 1) cross-sectional area (CS.Ar: the
area of bone tissue bounded by the periosteal
surface, mm2), 2) medullary area (Me.Ar: the
area delineated by the endocortical surface,
mm2), 3) Cortical width (Ct.W, mm) and 4)
Cross sectional moment of inertia (CSMI, mm4)
was calculated as ([periosteal diameter/2]4 –
[medullary diameter/2]4) * π/6424.
Mechanical testing
Femurs were stored at -20 ºC wrapped in
saline-soaked gauze. For mechanical testing,
they were thawed at 37°C. Cortical bone
strength at the femoral mid-diaphysis was deter-
mined using a three-point bending test and
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Figure 1. Scheme of measurement sites on cartilage.
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trabecular bone strength was evaluated by a
compression test on a 2.5-mm thickness
transversal section from distal epiphysis28,29.
Mechanical testing was performed on a machine
designed at the engineering department of the
Bone Biology Laboratory, with a 300 N load cell
with 0.01 N of discrimination and an accuracy of
10 µm in displacements. The two-bar distance
for the three-point bending test was 12 mm at
T15 and 13 mm at T30. The compression test
was performed with a compression cone of 7.07
mm2 and a speed of 0.01 mm/s was used for
both tests. Load vs. displacement plots were
recorded by a software (Biomedical Data
Acquisition Suite 1.0, Argentina, 2011) to deter-
mine bone structural properties. The software
data acquisition rate was 10 Hz. Ultimate load
(N) was defined as the highest load and the
fracture load (N) was recorded just before the
first decline in load. The stiffness (N/mm) was
determined as the slope of the linear portion of
the load vs. displacement curve. Absorbed
energy (mJ) was defined as the area under the
curve until the fracture load point.
Statistical analysis
Data were expressed as mean ± SD. Two-
way analysis of variance (ANOVA) was perfor-
med with D of ZA and T as analyzed factors.
The multiple comparison Bonferroni post-test
was performed if significant interaction was
found. If there was no interaction between
variables, it was indicated only if there was
D or T effect. Differences were considered
significant if p<0.05. Statistical analyses were
performed using the software R 2.14.0.
Results
Bone and growth plate growth
Femoral length was affected by both D and T.
As expected, a significant increase in femoral
length was observed at 30 days compare to 15
days at all doses. However, a significant inter-
action between D and T was observed and after
30 days of treatment, femur length was lower at
D25 than D0, D2.5 and D12.5. In addition, tibial
length and most cartilage parameters were sig-
nificantly affected by both D and T (Figure 2).
Although no interaction between D and T was
found, tibial length and GPC.Th showed lower
values at D25 than D0, D2.5 and D12.5 after 30
days of treatment. Moreover, GPC.Th showed
the lowest value at D25 also after 15 days of
treatment. The R&PZ.Th and HpZ.Th was
affected by D and T in a similar way as GPC
(data not shown).
INSERTAR FIGURE2
Table1 shows that all parameters that
evaluate appositional growth were affected by
the period of treatment. Moreover, the D also
affected CS. Ar, Me.Ar and Ct.W. Interaction
between D and T was observed only for Me.
Ar where lower values were found at the
highest dose in both periods of treatment. Even
though there was no significant interaction
between D and T in CS.Ar lower values were
also observed at D25. However, the Ct.W was
not negatively affected since higher values
were found at all ZA doses than D0 at both
period of treatment.
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Figure 2. Effects of ZA dose accumulation on bone and
growth plate growth. All parameters were significantly
affected by the period of treatment. Two-way ANOVA,
p<0.05.Values bearing different letters between bars are
significantly different (Bonferroni post-test, showed in
case of interaction only).
Actualizaciones en Osteología, VOL. 14 - N° 3 - 2018
Lupión P.M., et al.: Zoledronic acid effect on bone
172
Two-way ANOVA, Bonferroni post-test (for interaction only). Values bearing different letters between columns are
significantly different (p<0.05). Abbreviation = D: ZA doses; T: period of treatment; D-T: dose and time interaction;
CS.Ar: cross-sectional area; Me.Ar: medullary area; Ct.W: Cortical width.








Radiographs showed the characteristic
radiodense lines in the metaphyses of ZA
treated rats that corresponded to the number of
administered doses (2 or 4). BMD was only
affected by T (Two-way ANOVA, p<0.05) and
no interaction between D and T was observed
(T15 days:D0=10.34±3.67 mg Ca/cm2,
D2 .5=7 .84±2 .97 , D12 .5=11 .56±2 .39 ,




D but not T had effect on most histomorpho-
metric parameters (Table 2). A significant effect
of T was found only on Tb.N. The higher BV/TV
in D12.5 and D25 after 15 and 30 days of
treatment was due to an increased in Tb.Th and
Tb.N.
Figure 3. Representative images (40x) of trabecular bone of tibiae showing the effect of dose at 30 days of treatment.
A: D0, B: D2.5, C: D12.5 and D: D25.
15 days 30 days Two-way ANOVA
0 2.5 12.5 25 0 2.5 12.5 25 D T D-T
5.61±0.59 5.07±0.57 5.34±0.50 4.94±0.42 7.47±1.52 7.53±0.64 7.63±0.36 6.65±0.44 p<0.05 p<0.05 ns
2.87±0.47a 2.26±0.23bc 2.39±0.25bc 2.07±0.18c 2.70±0.47ab 2.98±0.49a 2.93±0.25a 2.39±0.25c p<0.05 p<0.05 p<0.05
0.61±0.10 0.62±0.14 0.80±0.21 0.68±0.08 1.00±0.15 1.05±0.23 1.17±0.16 1.15±0.25 p<0.05 p<0.05 ns
15 days 30 days Two-way ANOVA
0 2.5 12.5 25 0 2.5 12.5 25 D T D-T
29.02±11.68 30.96±9.63 41.08±0.65 49.90±9.48 31.36±7.10 39.20±6.27 50.20±7.41 50.14±1.98 p<0.05 ns ns
36.50±8.02 35.50±5.99 44.80±6.33 47.30±9.11 37.30±1.85 39.40±1.17 43.00±2.65 44.00±6.03 p<0.05 ns ns
7.81±1.44 8.63±1.40 9.26±1.16 10.57±0.56 8.43±1.94 9.90±1.57 11.69±1.51 11.49±1.05 p<0.05 p<0.05 ns
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Two-way ANOVA. Abbreviation = D: ZA doses; T: period of treatment; D-T: dose and time interaction; BV/TV: bone
volume; Tb.Th: trabecular thickness; Tb.N: trabecular number; Tb.Sp: trabecular separation
Table 2. Bone histomorphometry measurements
15 days 30 days Two-way ANOVA
0 2.5 12.5 25 0 2.5 12.5 25 D T D-T
0.35±0.11 0.63±0.40 0.41±0.01 1.05±0.06 0.59±0.39 0.78±0.28 1.64±0.51 2.70±1.18 p<0.05 p<0.05 ns
0.31±0.09 0.40±0.11 0.36±0.07 0.58±0.01 0.34±0.07 0.54±0.13 0.61±0.11 0.72±0.13 p<0.05 p<0.05 ns
0.13±0.05 0.15±0.01 0.22±0.01 0.20±0.04 0.14±0.01 0.17±0.01 0.18±0.01 0.17±0.02 p<0.05 ns ns








Two-way ANOVA. Abbreviation = D: ZA doses; T: period of treatment; D-T: dose and time interaction; ICI: intercon-
nectivity index; R: node-to-termini ratio; Dist: mean size of branches; NTm: number of branches with two terminals.
Table 3. Trabecular connectivity assessment
Connectivity parameters were affected by D
and T except for Dist which only was affect by
the D (Table 3). Despite no interaction between
both factors, higher ICI and R values were
found in groups with D12.5 and D25 after 15
and 30 days of treatment showing an increase
in trabecular connectivity. Moreover, the NTm
parameter, which provides information about
loss of connectivity in the bone architecture,
was decreased in all groups treated with ZA
independently of the length of treatment.
Mechanical testing
Biomechanical parameters of cortical bone,
analyzed with three-point bending test and the
CSMI were affected only by length of treatment
(Table 4), except for absorbed energy, which
was affected by both factors. On the other
hand, trabecular biomechanical parameters
such as fracture load and stiffness were affec-
ted by the D and T. Also, significant interaction
between D and T was observed, with higher
values in fracture load and stiffness at all ZA
doses compared with D0 after 30 days of
treatment. No effect on the absorbed energy
was found in the compression test (Table 4).
Discussion
The use of BP in children and adolescents
with bone diseases is increasing since they
have provided significant clinical improvements
such as decreased of pain, lower incidence of
fractures, and better mobility5,6,13,20. However,
their use in childhood is still controversial
because there are very few preclinical experi-
ments and clinical trials30. Despite the pamidro-
nate intravenous infusion is being the most
used treatment in children and adolescents
with bone diseases, ZA is being used more
frequently because of its higher potency and
reduced frequency of infusion. However, the ZA
efficacy and safety have not been thoroughly
evaluated31, raising concerns on whether the
drug may interfere with normal bone growth18,32.
Here, we investigate the effects of ZA on
bone properties in growing female normal rats
using increasing doses, equivalent to different
therapeutic situations in humans18,30,33 after two
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periods of treatment in order to analyze the
effect of dose accumulation. In spite of the
increasing cumulative dose of ZA, all bone
parameters were improved according to the
expected growth through the experiment.
However, linear and appositional growth were
negatively affected under the treatment with the
highest cumulative dose of ZA. Femoral and
tibial length were lower at D25 compared to D0,
D2.5 and D12.5 after 30 days of treatment, an
effect that was not found after 15 days of treat-
ment indicating that the cumulative dose of ZA
could affect bone growth. On the other hand,
GPC.Th was affected by the highest ZA dose
from 15 days of treatment. These early effects
on the growth plate could explain the ZA effect
on femur and tibia growth after 30 days of
treatment. These findings are consistent with
previous studies. Thus, Oyhanart et al showed
that alendronate interferes with long-bone and
mandibular growth14. In addition, a study in mice
with osteosarcoma treated with ZA showed a
decrease in tibial length18. Moreover, a decrease
in tibial longitudinal growth rate was observed
after pamidronate or ZA administration in
growing rats34. The effect on longitudinal growth
might be due to the ZA action on osteoclasts
since they play an important role in the process
of endochondral ossification.
Nevertheless, studies in pediatric patients
with osteoporosis treated with ZA showed that
longitudinal growth was unaffected during
treatment33,21. This is consistent with our results
because at low doses -similar to those used for
osteoporosis- no longitudinal growth alteration
was observed, independently of the length of
treatment evaluated in this study. However, the
effect of BP on bone length might depend on
type, dose, and frequency of BP and age or
medical history of the patient and the possibility
of a decrease in children height should be
considered and monitored.9
Linear growth has been a concern in pedia-
trics patients treated with BP, but the apposi-
tional growth has received less attention,
although it is important for the development of
the skeleton, being one of the determinants of
bone strength35. During bone growth, bone
formation is uncoupled to resorption to shape
the bone through modeling. Consistent with this
action of osteoclasts, it has been observed in
patients with osteogenesis imperfecta treated
with pamidronate that this drug interferes with
periosteal resorption, process that is normally
responsible for the shape of the distal femoral
metaphysis36. Also BP inhibit endosteal resorp-
tion but not periosteal apposition resulting in an



















Two-way ANOVA, Bonferroni post-test (for interaction only). Values bearing different letters between columns are
significantly different (p<0.05). Abbreviation = D: ZA doses; T: period of treatment; D-T: dose and time interaction.
Table 4. Mechanical testing
15 days 30 days Two-way ANOVA
0 2.5 12.5 25 0 2.5 12.5 25 D T D-T
Three-point bending test
32.87±3.55 34.34±5.38 34.85±3.29 35.97±1.70 57.18±5.49 56.00±13.89 64.17±6.93 64.39±10.37 ns p<0.05 ns
37.24±2.68 37.73±2.06 38.64±3.64 37.49±1.70 59.70±6.45 62.94±5.33 65.85±5.34 66.45±10.89 ns p<0.05 ns
71.39±19.06 71.20±7.23 102.50±38.47 85.28±37.47 158.40±38.4 133.50±39.10 149.70±60.74 289.90±239.60 ns ns
29.48±7.16 27.37±5.73 30.13±6.05 27.44±1.98 48.07±9.35 55.66±11.85 62.72±6.01 44.27±13.82 p<0.05 p<0.05 ns
1.27±0.62 0.97±0.49 1.41±0.58 1.11±0.58 2.23±0.62 2.68±1.30 2.84±0.50 3.14±0.36 ns p<0.05 ns
Compression test
25.45±5.94a 37.61±35.12a 53.49±22.91a 37.75±25.49a 35.75±7.96a 106.90±35.07b 111.20±34.12b 126.40±33.57b p<0.05 p<0.05 p<0.05
162.00±99.75a 197.00±141.90a 254.80±132.80a 154.80±109.40a 209.40±84.13a 572.00±291.30ab 885.10±534.40bc 1085.80±813.30c p<0.05 p<0.05 p<0.05
12.63±18.62 11.46±10.53 9.12±10.80 6.85±11.54 5.55±3.79 12.83±7.59 16.98±12.85 14.82±9.08 ns ns ns
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strength37. In our study all morphometric para-
meters -used to evaluate appositional growth-
were affected by D and T. Only D25 showed a
mild negative effect on CS. Ar but that was
counteracted by a decreased of Me. Ar avoiding
affect Ct.W and achieving a better distribution
of material as shown by CSMI after 30 days of
treatment. At the shorter period of treatment (15
days), an 11.8% decrease on Cs. Ar and a 27%
decrease on Me. Ar were found indicating a
rapid inhibition of bone resorption. This led to an
increase of Ct.W indicating that bone resorption
was inhibited by ZA therapy but activity on
periosteal surfaces was less affected as deter-
mined in modeling. The mechanical properties
of cortical bone were increased by the period of
treatment and only the absorbed energy was ne-
gatively affected by the ZA dose. However, this
negative effect of the highest ZA accumulated
dose on absorbed energy and CS. Ar was not
enough to decrease bone strength. This could
be due to the greater CSMI shown at D25 after
30 days of treatment indicating a better spatial
distribution of material that is highly correlated
with bone strength as mentioned above38.
The bone mass acquired during the growth
was evaluated by BMD and the percentage of
bone volume. BMD was only affected by the
period of treatment. The lack of significant dose
effect could be due to the low sensitivity of the
technique and would be a limitation of this
study. However, ˜20% increase in a BMD was
observed at D25 after 30 days of treatment
which could be explain by the increase in
trabecular bone volume. Furthermore, the
trabecular bone volume was increased with all
ZA doses after 15 and 30 days of treatment as
a consequence of increase in both trabecular
thickness and, mainly, in trabecular number.
The latter could be due to the fact that
antiresorptive therapy led to a lesser resorption
of primary trabeculae that, necessarily, became
secondary trabeculae39. In addition, the
connectivity indexes also increased with dose
and the length of treatment, indicating an
improved bone architecture, which could impact
on the biomechanical evaluation. These finding
matched the observations by Pataki et al.34
but were different to those conducted in
children with osteogenesis imperfecta where
the increase in bone volume was due only to an
increased in trabecular number but without any
effect on trabecular thickness39.
On the other hand, the compression test,
which evaluates the trabecular mechanical
properties, showed a favorable effect of dose
and the length of treatment on fracture load and
stiffness –without changes in absorbed energy.
In addition, an interaction of both factors was
found in fracture load and stiffness. The impro-
ved trabecular mechanical properties could be
attributable not only to the increased bone
volume but also to the bone microarchitecture
since better connectivity parameters were
found. Although not significant, a borderline p
value (p=0.07) for interaction was found in ICI
parameter indicating that the trabecular connec-
tivity would be greater at the highest dose of ZA.
In summary, our results indicate that ZA treat-
ment would not have significant negative effects
on the mechanical properties of the growing
bone. Moreover, an improved on trabecular
parameters were observed in all ZA doses.
Some limitations of this study must be
pointed out. The experiment was carried out
with healthy animals and these findings should
be confirmed using experimental models of
bone diseases. On the other hand, the conver-
sion of equivalent doses between human and
rats, and the possible different pharmaco-
dynamics of ZA between them should be
highlighted. However, in spite of limitations, this
work carried out a complete bone analysis
assessment, including morphometric, densito-
metric, histomorphometric and biomechanical
analysis. Therefore it contributes to current
knowledge on the effects of ZA dose accumula-
tion on bone growth.
In conclusion, even though a mild negative
effect of the highest dose of ZA on linear and
appositional growth were observed; bone
volume, trabecular connectivity and trabecular
mechanical properties of growing bone were
improved also at the highest cumulative ZA
dose. As the highest dose was comparable to
those used in models of bone pathologies
related to primary tumors or bone metastasis,
a careful risk/benefit analysis would lead us to
conclude that the mild deleterious effects of ZA
during growth are outweighed by the benefit
obtained with treatment.
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